key: cord-1042356-wq7c4jsw
authors: Conway, Edward M.; Pryzdial, Edward L.G.
title: Is the COVID‐19 thrombotic catastrophe complement‐connected?
date: 2020-08-06
journal: J Thromb Haemost
DOI: 10.1111/jth.15050
sha: 74fdf411d1a5051e12086a42d307e7186bcb852a
doc_id: 1042356
cord_uid: wq7c4jsw

In December 2019, the world was introduced to a new betacoronavirus, referred to as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) for its propensity to cause rapidly progressive lung damage, resulting in high death rates. As fast as the virus spread, it became evident that COVID‐19 is a multi‐system disease, that may involve multiple organs, and has a high risk of thrombosis, associated with striking elevations in pro‐inflammatory cytokines, D‐dimer and fibrinogen, but without disseminated intravascular coagulation. Postmortem studies have confirmed the high incidence of venous thromboembolism (VTE), but also notably revealed diffuse microvascular thrombi with endothelial swelling, consistent with a thrombotic microangiopathy (TMA), and inter‐alveolar endothelial deposits of complement activation fragments. The clinicopathologic presentation of COVID‐19 thus parallels that of other thrombotic diseases, such as atypical hemolytic uremic syndrome (aHUS), that are caused by dysregulation of the complement system. This raises the specter that many of the thrombotic complications arising from SARS‐CoV‐2 infections may be triggered and/or exacerbated by excess complement activation. This is of major potential clinical relevance, as currently available anti‐complement therapies that are highly effective in protecting against thrombosis in aHUS, could be efficacious in COVID‐19. In this review, we provide mounting evidence for complement participating in the pathophysiology underlying the thrombotic diathesis associated with pathogenic coronaviruses, including SARS‐CoV‐2. Based on current knowledge of complement, coagulation and the virus, we suggest lines of study to identify novel therapeutic targets and the rationale for clinical trials with currently available anti‐complement agents for COVID‐19.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic 1 continues to spread, a rising cause of morbidity and mortality 2 . Although the course of COVID-19 varies, the most severe manifestations are catastrophic multi-organ failure with widespread inflammation, microvascular thrombosis, and increased risk of venous thromboembolism [3] [4] [5] [6] [7] [8] [9] . In spite of comprehensive intensive care with cardiorespiratory support, anti-inflammatory agents, antibiotics where needed, and anticoagulants 10 , there are still no proven effective therapies 11,12 , and death rates remain high. This highlights the critical need to expand our knowledge of the pathophysiological mechanisms underlying the dramatic host response to SARS-CoV-2 infection, toward the design of urgently needed diagnostic and therapeutic strategies.

The aggressive nature of COVID-19 is reminiscent of other rapidly progressive, organ-damaging, thrombotic disorders where innate immune host responses escalate out of control. This is exemplified by the thrombotic microangiopathy (TMA), atypical hemolytic uremic syndrome (aHUS), where the major multi-protein, blood-borne component of the innate immune system, complement, is overactivated due to loss-of-function or gain-of-function mutations in complement regulatory genes 13 .

Prior to the introduction of the anti-complement drug, eculizumab 14, 15 , aHUS episodes, often triggered by a preceding viral illness, commonly resulted in accelerated microvascular thrombosis and multiorgan damage, with a high mortality rate, similar to what is all too often seen with COVID-19. There are compelling arguments to support the notion that complement over-activation also participates in SARS-CoV-2-triggered thrombosis and multi-organ failure. We hypothesize that many of the manifestations of COVID-19 are mediated in part by excess activation of complement, initiated directly by virus surface constituents and infected cell modulation, overall contributing to the thromboinflammatory tempest. If this is true, administration of available and/or newly developed anticomplement therapies might be beneficial toward improved outcomes for COVID -19. In this review, we describe the links between complement and coagulation, the evidence that supports a role for complement in COVID-19, potential mechanisms by which SARS-CoV-2 triggers complement activation and thromboinflammation, underline some of the challenges and

This article is protected by copyright. All rights reserved inconsistencies to this hypothesis, and propose several therapeutic strategies using existing drugs and new potential targets.

The complement system comprises >40 soluble and membrane-bound proteins, eliciting innate immune responses via opsonization, destruction and elimination of pathogens and damaged/apoptotic/infected host cells, and recruitment of inflammatory cells and adaptive immunity 16,17 . Following recognition of pathogen-and/or danger-associated molecular patterns (PAMPs and DAMPs, respectively), complement is activated in a cascade-like fashion via three pathways. These have in common, the generation of potent biological effectors, including the covalent deposition of C3b onto foreign particles for macrophage-targeting, the production of chemotoxins and anaphylatoxins, C3a, C4a and C5a, and the membrane-insertion of a lytic membrane attack complex (MAC). These trigger an inflammatory response and destruction of the invading pathogen. (Figure 1 )

The lectin and classical pathways (LP and CP, respectively) are triggered by interactions of mannose binding lectin (MBL) and C1q, respectively, to pathogens and damaged cells. This leads to generation of MBL-associated serine proteases (MASPs) 18 for the LP, and C1r and C1s for the CP. MASP-2 and C1s have in common that they cleave C2 and C4 to generate the CP/LP C3 convertase, C4b2b, with liberation of C3a and C4a. The alternative pathway (AP) is constitutively "on" by virtue of continuous hydrolysis of C3 to C3(H 2 O), generating the C3 convertase, C3bBb, when factor B (FB) is cleaved by factor D. Thus, all pathways converge to form a C3-convertase, which proteolyses C3 into C3a and C3b; subsequently shifting in specificity to C5-convertase, proteolysing C5 to liberate C5b and C5a.

C5b assembles with C6, C7, C8 and C9 molecules to yield the MAC comprised of C5b-9. Mediated primarily by binding and signaling via their respective cognate receptors, C3aR and C5aR1/2, the anaphylatoxins C3a and C5a are potent biological effectors of the complement system. A thromboinflammatory response may be elicited by a broad range of effects, including recruiting leukocytes, and activating platelets and endothelial cells 19, 20 .

This article is protected by copyright. All rights reserved Several fluid-phase and membrane-anchored regulators strictly moderate and localize complement, including for example factor H (FH), C4bBP, CD46, CD55, CD59 and thrombomodulin [21] [22] [23] [24] [25] [26] [27] . Excess complement activation due to loss-of-function or gain-of-function mutations in these factors, notably causes thrombosis and resultant tissue damage as seen in aHUS and PNH [28] [29] [30] [31] . This is relevant to COVID-19, which is similarly strongly associated with vascular thrombosis and inflammation [32] [33] [34] [35] .

Several molecular and cellular mechanisms by which complement activation promotes coagulation have been delineated (reviewed 36,37 ) ( Figure 2 ). For example, the MASPs activate prothrombin, cleave fibrinogen to fibrin, enhance factor XIIIa activity, and activate protease activated receptors (PARs) [38] [39] [40] [41] (Figure 3 ). C5a triggers release of prothrombotic factors from platelets, induces expression of the coagulation initiator tissue factor (TF) on endothelial cells and monocytes 42, 43 , and suppresses expression of natural anticoagulant proteins. C5a furthermore induces P-selectin exposure which is a C3b receptor 20 , thus providing a site on the platelet for C3/C5 convertase assembly, amplifying complement activation. C5b-7 activates TF on monocytes 44 , and C5b-9 activates platelets and endothelial cells and promotes TF procoagulant function [45] [46] [47] . Notably, the key complementinduced procoagulant factors, thrombin and TF 48, 49 , feedback and amplify complement activation, thereby sustaining a vicious, escalating, and tissue-damaging cycle. This is further exacerbated by the virus itself, which may acquire and express host TF [50] [51] [52] [53] . Overall, there is an often overlooked but relevant bi-directional interplay between complement and coagulation, which may help explain the high incidence of thrombosis in COVID-19.

Serious epidemics have recently been caused by betacoronaviruses with significant homology to SARS-CoV-2, these being SARS-CoV-1 and MERS-CoV. A review of the clinical and pathological findings in survivors and non-survivors of SARS-CoV-1 infection, revealed a high incidence of VTE, as well as microvascular thrombosis involving multiple organs 3 , like COVID-19. Although data are more limited, the epidemic due to MERS-CoV was also associated with a high risk of VTE 3 .

Interestingly, transgenic overexpression in mice of the receptor responsible for MERS-CoV entry into

This article is protected by copyright. All rights reserved cells, resulted in a virus-triggered, rapidly progressive pulmonary disease, with diffuse microvascular thrombosis 54 . Combined with SARS-CoV-2, these findings imply that thrombosis of large and small vessels are typical clinical characteristics of the betacoronavirus genus. But does complement participate, and if so, how?

Preclinical studies with SARS-CoV-1 and MERS-CoV, support the notion that complement activation is not only associated with virus-related organ damage, but is likely causative. In mouse models, intranasal administration of MERS-CoV 55 triggered inflammatory lung damage, with increased deposition of C5b-9, and elevated circulating levels of C5a, IL-1, TNF and IFN. Inhibition of C5aR with specific antibodies, reduced complement activation, alleviated the lung damage, and limited viral replication. By a similar approach, Gralinski et al 56 administered SARS-CoV-1 to mice, inducing lung damage with increased tissue deposition of C5b-9, C3b and C4d, amounts of which correlated with severity of injury. A role for complement activation in this adverse viral response, was confirmed by the marked reduction in lung pathology and cytokine release when the virus was administered to mice deficient in C3. Protection was also afforded to mice lacking C4 and factor B (FB), but to a lesser extent than with C3-deficiency. These data implicated both the AP and the CP/LP as mediating the SARS-CoV-1 triggered lung injury 56 .

Other studies have revealed direct interactions of these coronoviruses with components of the LP. In vitro, MBL binds to immobilized SARS-CoV-1 likely via surface glycans, and enhances C4 deposition on the virus in a mannan-dependent manner 57 

Taken together, the preceding evidences strongly suggest that there is a direct correlation between the complement overactivation and thrombopathies associated with infections with SARS-CoV-1 and MERS-CoV. Similarly, the data for complement participating in the pathogenesis of thrombosis and end-organ damage associated with COVID-19, albeit less abundant, are nonetheless supportive. In the few post-mortem studies of COVID-19 patients that have been published, there were increased interalveolar endothelial deposits of MBL, MASP-2, C4b, C3b and C5b-9 33,61 , as well as C5b-9 deposits in the glomeruli of kidneys 62 . These reports are in line with excess activation of the LP, as appears to occur with the other pathogenic coronaviruses 58 . This is in fact not surprising, as the spike protein of SARS-CoV-2 is heavily glycosylated with L-fucose and mannose 63 , thereby providing recognition sites for MBL binding and activation of the LP. Providing a direct link to the thrombotic diathesis of patients with COVID-19, complement hyperactivation was accompanied by histopathologic evidence particularly in the lungs, comprising diffuse microvascular thrombi and endothelial swelling consistent with TMA -a hallmark of aHUS 33, 61 . This was not an isolated finding, as similar small

This article is protected by copyright. All rights reserved vessel changes with microthrombi were also observed in the largest autopsy series reported (12 patients) 9 . These disturbances of the vasculature may also be caused by direct endothelial invasion by SARS-CoV-2 via the ACE-2 receptor 64 , which would promote a prothrombotic and pro-inflammatory phenotype, with exposure of DAMPs and activation of the CP. Interestingly, although anemia, thrombocytopenia and particularly elevations in LDH are frequently observed in patients with COVID-19, fragmentation hemolysis is not a major feature. This does not, however, exclude a diagnosis of complement-mediated TMA, as even in active aHUS, schistocytes are not always detected on peripheral blood smear examination 65, 66 .

Overall, we propose that SARS-CoV-2 triggers complement activation through its recognition by the host as a foreign pathogen, by its acting as a cofactor to enhance LP activation, and by its invading and injuring ACE-2 receptor-expressing host cells. This inevitably promotes a thromboinflammatory response, which in turn, cycles back to further amplify complement activation and clotting. Proving this hypothesis will require clinical trials with anti-complement therapies, several of which are underway. These will be discussed below.

Despite the evidence that rapid onset of microvascular thrombosis and multi-organ failure following SARS-CoV-2 infections may at least in part, be mediated via hyperactivation of complement, major gaps remain in our understanding of the mechanisms and the reasons for the varied manifestations.

For example, is the classical pathway (CP) also involved? Is the increased risk of venous thromboembolism (VTE) and large vessel arterial thrombosis 34 in COVID-19 patients also complement-mediated? Does SARS-CoV-2 cause direct dysregulation of complement and is this an advantage to the virus? Can the often-profound pro-inflammatory response that accompanies thrombosis in COVID-19, be explained by complement activation? Why do children appear to either be spared from disease or sometimes follow a different course? Are there genetic variants in complement regulatory genes that determine severity of outcome? Finally, which therapeutic anticomplement interventions should be considered to best prevent/treat the thromboinflammatory response to SARS-CoV-2 infection?

This article is protected by copyright. All rights reserved

It has been speculated that following exposure to SARS-CoV-2, anti-viral IgM and IgG antibodies may be generated, resulting in immune complexes on the virus or the infected cell(s), thereby triggering complement activation via the CP 67 . Although reasonable, to our knowledge, this has not yet been demonstrated with any of the pathogenic coronaviruses, using available in vitro or in vivo models. This would be important to determine, as there are clinically tested, safe and available anticomplement therapies that specifically target C1s 68 , or both C1s and the MASPs, the latter through the use of C1-INH 69 .

The incidence of VTE in COVID-19 ranges from ~10-35% (reviewed 70 ), with autopsies indicating that it may exceed 50% 9 . The mechanisms underlying the thrombosis are entirely unknown. Although many of these patients have elevated D-dimer and fibrinogen, they also commonly have increased CRP and IL-6, consistent with a vigorous inflammatory response 35 . The thrombopathy may be a response to direct virus-induced damage to vascular endothelial cells 64 and/or the virus acquiring TF from host cells, both triggering coagulation activation 50, 52, 53, 71 . However, it is also possible that complement contributes. In contrast to aHUS, which causes a TMA with microvascular thrombi, the complement-mediated disorder, paroxysmal nocturnal hemoglobinuria (PNH), is strongly associated with VTE and arterial thrombosis 30, 31 

This article is protected by copyright. All rights reserved Complement activation products have been detected on erythrocytes of patients with COVID-19 73 , but the relevance of these findings have not been explored. It is conceivable that one or more of the SARS-CoV-2 proteases cleave GPI-anchored complement regulatory proteins from the surface of circulating or vascular endothelial cells, resulting in a PNH-like phenotype predisposing to large vessel thrombosis. The long-held view that complement activation occurs only in the circulation and on the surface of cells, pathogens and foreign surfaces has recently been supplanted by recent studies that reveal roles also for intracellular complement (referred to as the complosome) in immune cell regulation (reviewed 76 ). Indeed, most complement components, including C3, C5 and FH, may be synthesized by many immune and non-immune cells, including epithelial and endothelial cells. Intracellular activation of complement via cleavage of C3 and C5, can be triggered by pathogens such as viruses, leading to a strong proinflammatory cytokine response, with the release of, for example, IL-6, IL-1 and TNF 77 . Notably, it is these pro-inflammatory cytokines that are characteristically elevated in severe COVID-19, eliciting the so-called "cytokine storm" 35 .

This article is protected by copyright. All rights reserved

The mechanisms underlying the prominent COVID-19-associated hyper-inflammatory response are not well understood. However, excess complement activation by itself is not a plausible explanation, as this phenomenon is not observed in aHUS. Extensively reviewed by others 78 

The clinical spectrum following SARS-CoV-2 infection ranges from asymptomatic to critically ill, with severity highest in the very elderly, particularly in those with pre-existing comorbidities, and lowest in children. Although children and adolescents have a low incidence of symptomatic infections as compared to adults, those who do require hospitalization, may suffer from what has been termed a "multisystem inflammatory syndrome in children (MIS-C)" 83 . Sharing features with other rare disorders, including Kawasaki disease, toxic shock syndrome and hemophagocytic lymphohistiocytosis 84 , the presentation is distinct from adult COVID-19. Although varied, these patients suffer from cardiovascular shock with myocardial dysfunction, fever, mucocutaneous lesions, rash, gastrointestinal disorders, thrombocytopenia, neutrophilia, evidence of acute kidney injury, and biochemical evidence of hyperinflammation. Strikingly, these younger individuals often lack severe pulmonary manifestations, and equally enigmatic, thromboembolic events are rarely seen 83 .

This article is protected by copyright. All rights reserved Complement activation has not reportedly been measured in these patients. Amongst various proposed explanations for the differing responses in children and adults, it is possible that agedependent differences in circulating ACE-2 and expression of the ACE-2 receptor by host cells may contribute to the lower incidence of lung disease and thrombosis [85] [86] [87] . Elucidating the pathogenic mechanisms for MIS-C will be key for optimal treatment and prevention.

As is evident from above, the determinants of susceptibility to infection, and the pattern and severity of illness remain poorly understood. Ramlall et al 88 all of which conferred a significantly increased risk of an adverse clinical outcome. Interestingly, these negative regulators of complement have also been linked to age related macular degeneration (AMD), another disorder that is most commonly manifest in the elderly 90 . Such information is not only further evidence of the important role that complement likely plays in COVID-19, but if validated, may be of value in risk assessments which in turn will impact on clinical decision making.

While the world searches for effective means of halting the spread of SARS-CoV-2, an array of strategic therapeutic approaches are being tested to shorten the course of COVID-19 and to limit the complications, including for VTE, inflammation and end-organ damage from microvascular thrombosis. Due to the complexity of the disease, it is readily apparent that multiple interventional strategies will be necessary to abrogate progression and to effect recovery and healing. It is also evident that current anticoagulant strategies will not be adequate to fully protect these patients from thrombosis; however, anti-complement drugs might be of benefit.

There are numerous potential sites in the complement system that may be targeted to help treat COVID-19. (Figure 1 ) Several anti-complement drugs are currently in the clinic, being evaluated or

This article is protected by copyright. All rights reserved used for a variety of complement mediated disorders. One or more of these may be well-suited for evaluation of efficacy for COVID-19.

Activation of the primary effector of complement, C3 would seemingly be a logical target to attenuate the thrombopathology in COVID-19. Compstatin derivatives that interfere with C3 convertase activity, include, for example APL-2 (Apellis Pharmaceuticals) and AMY-101 (Amyndas Pharmaceuticals). The safety of an approach that would suppress activation of all 3 pathways 91 in the setting of a viral infection has been reasonably questioned. However, such fears may be partly allayed by several lines of evidence: First, although children with inherited deficiency of C3 are more susceptible to infections, for unexplained reasons, they do not carry that risk into adulthood 92 . Second, pharmacologic suppression of C3 in non-human primates did not result in adverse effects. In fact, skin wounds of the C3-deficient animals tended to heal more rapidly 93 . Third, C3-deficient mice were protected against tissue damage triggered by SARS-CoV-1 infection 56 . Finally, AMY-101 has been used safely and apparently with benefit in a single adult patient with COVID-19 94 . It may be prudent to avoid using this approach in children with COVID-19.

The apparent prominent role of the LP in mediating the lung damage and thromboinflammatory response to all three of the pathogenic coronaviruses, suggests that this pathway might also be an ideal therapeutic target 95 . MASP-2 is the only LP protease that cleaves C4, and as noted above, also has direct procoagulant properties. Anti-MASP-2 monoclonal antibodies (OMS721, Narsoplimab) have been deemed to be safe for aHUS, and are being evaluated by Omeros Corporation in Phase 3 studies (reviewed 95 ). It would be interesting to test its efficacy in COVID-19. The anecdotal nature of all of the reports to date, necessitates cautious optimism that dampening complement activation is a valid therapeutic strategy to abrogate the thromboinflammatory sequelae of SARS-CoV-2 infections. And whichever anti-complement drug(s) is selected, one must consider the potential increased risk of infection due to loss of one or more components of the complement system, with early introduction of appropriate antibiotic and/or vaccination protocols 98 .

In terms of when to treat, we are of the opinion that early intervention for COVID-19 with anticomplement agents may be important to limit cell/tissue damage. Although a systematic evaluation of complement activation during COVID- 19 has not yet been performed, preliminary data from our lab (unpublished) and others 99 indicate that complement activation occurs early, with elevations in C5a and C5b-9 in patients with moderate disease. Could early dampening of complement activation and thus the innate immune response to the virus, worsen the disease? Theoretically, this could occur if intervention is too early, i.e. when SARS-CoV-2 infected individuals are asymptomatic or have mild disease. This should certainly be a consideration. In the least, when the disease is at a mild stage, it might be a good opportunity to vaccinate against encapsulated organisms or start the appropriate antibiotic coverage, in the case that more aggressive interventions, including anti-complement therapies, become necessary.

This article is protected by copyright. All rights reserved Overall, the question as to when to administer anti-complement agents and which ones to use, will only be answered with well-controlled clinical trials, informed in part by comprehensive studies that correlate severity of disease and outcomes, with biological markers of complement activation.

There is overwhelming evidence that the complement-thrombosis axis is a successful therapeutic target to mitigate disease in aHUS. Although the pathogenesis and progression of the multi-organ damage due to SARS-CoV-2 are different from aHUS, the clinicopathologic similarities justify consideration of complement as a therapeutic target to help to ameliorate the thromboinflammatory and organ-damaging manifestations of COVID-19. The deployment of existing anti-complement drugs with the aim of dampening the severity of COVID-19 may have obvious advantages. Using investigations with other betacoronaviruses and preliminary evidence gathered from SARS-CoV-2 as a paradigm, will furthermore spur the emergence of novel therapies. These may interfere with interactions between the SARS-CoV-2-encoded N-protein and MASP-2, the spike protein and MBL, or various other SARS-CoV-2-encoded proteins that are found to promote complement activation.

The development of small animal models to quickly assess their efficacy in abrogating virus-induced thromboinflammation will move these rapidly into the clinic for careful evaluation. 

This article is protected by copyright. All rights reserved 

A Novel Coronavirus from Patients with Pneumonia in China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

SARS-CoV-1, MERS-CoV and lessons from the past

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action

A rational roadmap for SARS-CoV

COVID-19 pharmacotherapeutic research and development. IUPHAR review "XXX

Pharmacologic Treatments for

COVID-19): A Review

Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype

Eculizumab for congenital atypical hemolytic-uremic syndrome

Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015. 16. Morgan BP. The complement system: an overview

Complement-targeted therapeutics

Stringent regulation of complement lectin pathway C3/C5

convertase by C4b-binding protein (C4BP)

Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells

Platelet activation leads to activation and propagation of the complement system

Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia

Extra-renal manifestations of complement-mediated thrombotic microangiopathies

Complement deficiency and disease

Proteases of the complement system

Hemolytic uremic syndrome

Platelet-associated complement factor H in healthy persons and patients with atypical HUS

Thrombomodulin mutations in atypical hemolyticuremic syndrome

Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS

Atypical Hemolytic Uremic Syndrome: A Brief Review

Paroxysmal nocturnal haemoglobinuria

Thrombosis in paroxysmal nocturnal hemoglobinuria

Acute pulmonary embolism and COVID-19 pneumonia: a random association?

Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans. MedRxiv (preprint, not peer-reviewed)

Accepted Article This article is protected by copyright. All rights reserved 34

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Cytokine storm and the prospects for immunotherapy with COVID-19

Reincarnation of ancient links between coagulation and complement

Complement-coagulation connections

Mannose-binding lectin-associated serine protease-1

is a significant contributor to coagulation in a murine model of occlusive thrombosis

Mannose-binding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation

The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen

Simultaneous activation of complement and coagulation by MBL-associated serine protease 2

Waterfall Sequence for Intrinsic Blood Clotting

Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid (aPL) antibodies. Blood

Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase

Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase

Tissue Factor at the crossroad of coagulation and cell signaling

Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development

Generation of C5a in the absence of C3: a new complement activation pathway

Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway

The procoagulant envelope virus surface: contribution to enhanced infection

Coagulation initiated on herpesviruses

Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease-activated receptor 2 cofactors that enhance infection

Virus envelope tissue factor promotes infection in mice

Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4

Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV

Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio

Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection

Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation

Sensitive and specific monoclonal antibody-based capture enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute respiratory syndrome

Nucleocapsid protein as early diagnostic marker for SARS

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases

Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MedRxiv (preprint, not peer-reviewed)

Site-specific glycan analysis of the SARS-CoV-2 spike

Endothelial cell infection and endotheliitis in COVID-19

Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome

Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand

Complement as a target in COVID-19?

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema

COVID-19 and its implications for thrombosis and anticoagulation

Antiviral anticoagulation

Genotype and phenotype of COVID-19: Their roles in pathogenesis

Erythrocytes Reveal Complement Activation in Patients with COVID-19. medRxiv

Factor H Family Proteins in Complement Evasion of Microorganisms

Accepted Article This article is protected by copyright. All rights reserved 76

Intracellular complement -the complosome -in immune cell regulation

Intracellular sensing of complement C3 activates cell autonomous immunity

Could SARS-CoV-2-Induced Hyperinflammation

Magnify the Severity of Coronavirus Disease (CoViD-19) Leading to Acute Respiratory Distress Syndrome? Front Immunol

The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?

Effects of IL-1beta, IL-6 and IL-8 on erythrocytes

Cytokine and chemokine regulation of venous thromboembolism

Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

COVID-19 Infection and Circulating ACE2 Levels: Protective Role in Women and Children

Will children reveal their secret? The coronavirus dilemma

Identification of immune complement function as a determinant of adverse SARS-CoV-2 infection outcome. BioRxiv (preprint not peerreviewed)

The UK Biobank resource with deep phenotyping and genomic data

Related Macular Degeneration: Implications of Gene-Environment Interaction for Preventive and Personalized Medicine

The case of complement activation in COVID-19 multiorgan impact

Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H

Safety profile after prolonged C3 inhibition

The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases

Plasma Instability when C1 Inhibitor is Absent

Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience

Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria

Complement activation in patients with COVID-19: A novel therapeutic target

Accepted Article

This article is protected by copyright. All rights reserved EMC and ELGP were equal contributors to writing and editing the manuscript. Both bear equal responsibility for the content.

The authors have no competing interests or conflicts.

This article is protected by copyright. All rights reserved